Rabies Treatment - Global Market Trajectory & Analytics

Global Rabies Treatment Market to Reach $5.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Rabies Treatment estimated at US$4 Billion in the year 2020, is projected to reach a revised size of US$5.1 Billion by 2027, growing at a CAGR of 3.4% over the period 2020-2027. Post-exposure Prophylaxis, one of the segments analyzed in the report, is projected to record 3.3% CAGR and reach US$3.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Pre-exposure Prophylaxis segment is readjusted to a revised 3.8% CAGR for the next 7-year period.



The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 6.3% CAGR

The Rabies Treatment market in the U.S. is estimated at US$1.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2027 trailing a CAGR of 6.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1% and 2.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Select Competitors (Total 46 Featured):

• Cadila Healthcare Ltd. (Zydus Cadila)
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• Pfizer, Inc.
• Sanofi SA